$-0.33 EPS Expected for TrovaGene, Inc. (TROV)

July 13, 2018 - By Nellie Rakes

TrovaGene, Inc. (NASDAQ:TROV) LogoInvestors sentiment increased to 0.75 in Q1 2018. Its up 0.22, from 0.53 in 2017Q4. It improved, as 4 investors sold TrovaGene, Inc. shares while 8 reduced holdings. 7 funds opened positions while 2 raised stakes. 2.63 million shares or 7.88% more from 2.44 million shares in 2017Q4 were reported.
Barclays Public Ltd Company accumulated 25,000 shares or 0% of the stock. Geode Management Ltd, Massachusetts-based fund reported 139,330 shares. Captrust Financial Advisors owns 62,500 shares or 0% of their US portfolio. Vanguard Gp reported 0% in TrovaGene, Inc. (NASDAQ:TROV). Virtu Financial Ltd Limited Liability Company holds 105,916 shares. Carroll Associates Inc holds 0% of its portfolio in TrovaGene, Inc. (NASDAQ:TROV) for 1,500 shares. Jpmorgan Chase Communication holds 811 shares or 0% of its portfolio. 290,000 were reported by Elkhorn Prns Limited Partnership. Deutsche National Bank Ag holds 71 shares or 0% of its portfolio. Meeder Asset Management Inc accumulated 5,433 shares or 0% of the stock. Morgan Stanley reported 4,220 shares or 0% of all its holdings. Tci Wealth Advsrs stated it has 0% of its portfolio in TrovaGene, Inc. (NASDAQ:TROV). State Street holds 0% or 13,300 shares. Cwm Limited Co reported 1,000 shares or 0% of all its holdings. Bnp Paribas Arbitrage Sa invested in 21 shares or 0% of the stock.

Analysts expect TrovaGene, Inc. (NASDAQ:TROV) to report $-0.33 EPS on August, 8.They anticipate $0.19 EPS change or 135.71 % from last quarter’s $-0.14 EPS. After having $-0.09 EPS previously, TrovaGene, Inc.’s analysts see 266.67 % EPS growth. The stock decreased 2.23% or $0.017 during the last trading session, reaching $0.741. About 258,144 shares traded. TrovaGene, Inc. (NASDAQ:TROV) has declined 63.33% since July 14, 2017 and is downtrending. It has underperformed by 75.90% the S&P500.

TrovaGene, Inc. (NASDAQ:TROV) Ratings Coverage

Among 2 analysts covering TrovaGene (NASDAQ:TROV), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. TrovaGene had 5 analyst reports since March 6, 2018 according to SRatingsIntel. On Monday, June 4 the stock rating was maintained by H.C. Wainwright with “Buy”. On Friday, June 15 the stock rating was upgraded by Maxim Group to “Buy”. The rating was maintained by H.C. Wainwright with “Buy” on Tuesday, March 6. H.C. Wainwright maintained the stock with “Buy” rating in Monday, June 11 report. H.C. Wainwright maintained the shares of TROV in report on Tuesday, June 19 with “Buy” rating.

Trovagene, Inc., a clinical-stage, precision medicine oncology therapeutics company, develops oncology therapeutics for cancer care by leveraging its proprietary Precision Cancer Monitoring technology in tumor genomics. The company has market cap of $17.01 million. The Company’s lead drug candidate, PCM-075, is a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor. It currently has negative earnings. The PCM-075 is an orally bioavailable, which has explored in preclinical antitumor activity as a single agent and in synergy combinations with approximately 10 different chemotherapeutics and targeted therapies, such as Zytiga (abiraterone acetate), Beleodaq (belinostat), Quizartinib, a development stage FLT3 inhibitor, and Velcade (bortezomib) in acute myeloid leukemia (AML), metastatic castration-resistant prostate cancer, and other liquid and solid tumor cancers.

Another recent and important TrovaGene, Inc. (NASDAQ:TROV) news was published by Streetinsider.com which published an article titled: “Trovagene (TROV) Announces Outlook for Second Half of 2018” on July 09, 2018.

TrovaGene, Inc. (NASDAQ:TROV) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.